Scholar Rock Holding (SRRK) Stock Price, Quote, News & History | Benzinga

Scholar Rock Holding Corp (SRRK) Stock Price, Quote, News & History

SRRKNASDAQ

Trade with Public

Trade with Public

$56.10

0.210.38%

At close: Sep 2, 5:00 PM EST

$56.36

0.260.47%

After Hours: 5:33 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$56.62

Close

$56.10

Volume / Avg.

1.07M / 1.31M

Day Range

$55.27 - $58.10

52 Wk Range

27.07 - 61.76

Market Cap

$6.86B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

18.67%

Days to Cover

19.82

Recent Scholar Rock Holding Corporation News

Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule

Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping the September 30 approval date on schedule.

Vandana Singh

Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on top names. For a complete view of all rating changes, see analyst ratings page.

Avi Kapoor

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave Life, Perimeter Solutions, Praxis Precision, and Century Aluminum.

Avi Kapoor

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function improvements.

Vandana Singh

Why Is Scholar Rock Holding Stock Climbing Today?

Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.

Nabaparna Bhattacharya

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-296.83M

Investing Cash Flow (TTM)

87.83M

Financing Cash Flow (TTM)

494.66M

Free Cash Flow (TTM)

-297.01M

Capital Expenditure (TTM)

-185.00K

Net Change in Cash (TTM)

285.67M

Analyst Trends and Forecast

6

Mar

2

Apr

2

May

1

Jul

4

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.52B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

26.82

Earnings Yield % (TTM)

-5.92%

Earnings Yield % (FWD)

-4.04%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.08

Company Debt

Total Debt

$196.20M

LT Debt

$196.20M

LT Debt Issuance (TTM)

$247.72M

LT Debt Repayment (TTM)

-$103.06M

Total Cash

$437.09M

Debt to Equity

0.80

Issuance of Debt (TTM)

$144.66M

Repayment of Debt (TTM)

-$103.06M

Key Statistics

Open

$56.62

Close

$56.10

Volume / Avg.

1.07M / 1.31M

Day Range

$55.27 - $58.10

52 Wk Range

27.07 - 61.76

Market Cap

$6.86B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

18.67%

Days to Cover

19.82

About

Sector

Health Care

Industry

Biotechnology

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab a...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Scholar Rock Holding (SRRK) stock?

A

You can purchase shares of Scholar Rock Holding (NASDAQ:SRRK) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Scholar Rock Holding (SRRK) competitors?

A

Other companies in Scholar Rock Holding’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Scholar Rock Holding (SRRK) stock?

A

Scholar Rock Holding has a consensus price target of $53.19.

Q

What is the current price for Scholar Rock Holding (SRRK)?

A

The stock price for Scholar Rock Holding (NASDAQ: SRRK) is $56.3633 last updated September 2, 2026 at 5:33 PM EDT.

Q

Does Scholar Rock Holding (SRRK) pay a dividend?

A

There are no upcoming dividends for Scholar Rock Holding.

Q

When is Scholar Rock Holding (NASDAQ:SRRK) reporting earnings?

A

Scholar Rock Holding does not have any upcoming earnings scheduled.

Q

Is Scholar Rock Holding (SRRK) going to split?

A

There is no upcoming split for Scholar Rock Holding.

Q

What sector and industry does Scholar Rock Holding (SRRK) operate in?

A

Scholar Rock Holding is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.